"I agree absolutely that a buyout of everything to do with CVD, diabetes, CKD, PAH, and cognitive function would make most sense for a single large company. But RVX could (and in my opinion should) hang onto HIV"

How would this be structured? Most companies sell compounds or platforms, not indications. With thousands of compounds in the BET inhibitior library (some with substantial pre-clinical validation) that could potentially be developed for the same indications as apabetalone, how would you envisage a buyout of an indication or subset of indications for one single compound (apabetalone) while preserving the company's ability to develop the same compound for a reserved number of indication(s)?

I see Golfyeti had similar response to Cityslicker before me too.

Makes more sense to me to sell or license apabetalone, while treating the rest of the compound library IP as an entirely different asset. Same logic for Zenith Epigenetics and ZEN-3694. 

BDAZ